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Abstract 
The inability to effectively halt or cure Alzheimer’s Disease (AD), exacerbated by the recent 
failures of high-profile clinical trials, emphasizes the urgent need to understand the complex 
biochemistry of this major neurodegenerative disease. In this paper, ten central, current 
challenges of the major paradigm in the field, the amyloid hypothesis, are sharply formulated. 
These challenges together show that new approaches are necessary that address data 
heterogeneity, increase focus on the proteome level, use available human patient data more 
actively, account for the aging phenotype as a background model of the disease, unify our 
understanding of the interplay between genetic and non-genetic risk factors, and combine into 
one framework both the familial and sporadic forms of the disease.  
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Introduction 
Alzheimer's Disease (AD) is one of the major health challenges of the 21st century: Based on 
data from the World Health Organization[1] and Alzheimer International[2], one can estimate 
that ~30 million people have AD world-wide as of 2016, and prevalence continues to grow. In 
2010, a meta-analysis  estimated 35.6 million dementia cases[3], corresponding to 21−25 million 
AD cases (60−70% of dementia cases are classified as AD), implying an annual growth in 
prevalence of 1½ million. The persistent deterioration associated with the disease is devastating 
to patients and relatives alike, and the prospected socio-economic burden of AD in an 
increasingly aged population threatens to undermine future healthcare budgets[4].  
In the wake of the early successes of the major mechanistic AD paradigm, the amyloid 
hypothesis[5][6], the field has experienced clinical disappointments, biochemical confusions, 
and new arising theories[7][8][9]. Accordingly, our ability to treat the disease remains deeply 
unsatisfactory, with current treatments only delaying disease progression by months[10][11]. 
The recent failure of high-profile drug candidates has been a painful wake-up call that has 
intensified the debate regarding disease mechanisms and treatment strategies[7][8][12][13].   
 AD is a complex multi-factor disease: It occurs mostly sporadically (>95% of cases) with 
very limited inheritance, it has a broad clinical spectrum[14], age is the main risk factor[15], and 
the disease manifests slowly as mild cognitive impairment[14][16][17] and subsequently leads to 
loss of cognitive capabilities, identity, and activity[18][19]. The complexity is evident from the 
multiple genetic, life-style, and environmental risk modifiers[20][21].  
 Genetic variations in the genes coding for the amyloid-β protein precursor (APP)[22] and 
the two presenilin isoforms PSEN1 and PSEN2[23][24] cause special early-onset familial forms 
of AD (FAD)[25][26][27]. Thus, APP and PSEN have constituted the main basis for 
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understanding AD, leading to the amyloid hypothesis discussed in this paper[6][28][29]. In 
addition, the apolipoprotein E ε4 allele (ApoE4) increases risk by several times for heterozygote 
carriers and by up to 15-fold for homozygotes[30][31][32]. Many other DNA loci have been 
identified from genome-wide association studies (GWAS) to possibly confer some risk of 
AD[33][34]. Some notable ones are BIN1, GAB2, GALP, ABCA7, TNK1, TREM2, PICALM, and 
CLU; many of these are involved in membrane transport, endocytosis, immune system, and/or 
lipid metabolism[25][34][35][36][37].  
 Among life-style related risk factors associated with dementia (but not yet clearly 
separated from AD), the most important are smoking[38], alcohol usage[39][40], body mass 
index[41][42], diabetes[43][44], hypertension[45], physical and mental inactivity[46][47][48], 
and depression[49][50]. Activity and education[20][51] and particular diets such as anti-oxidant-
rich Mediterranean and Indian cuisines[52][53][54] can reduce risk of dementia[55][56][57].  
 
The amyloid hypothesis 
The Aβ peptides that constitute the plaques characteristically found in patients have historically 
been a natural starting point for understanding the disease. Aβ is produced from APP found in 
the membranes of cells and organelles upon protein cleavage by β- and γ-secretases[58][59]. 
Furthermore, PSEN is the catalytic unit of the γ-secretase complex that degrades (among other 
substrates such as Notch[60]) APP into Aβ[61]. Thus, the two major genetic risks of FAD, PSEN 
and APP, suggest a role of Aβ in AD, providing support for the dominating paradigm of AD, the 
amyloid hypothesis[6][28].  
 The early version of the amyloid hypothesis, often referred to as the amyloid cascade 
hypothesis[5][28], asserted that toxic A-overload is the cause of AD: It was inspired by the 
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observed amyloid deposits in AD brains that could suggest an overload mechanism at play[62]. 
The finding that the plaques consist of Aβ peptides provided support for the amyloid 
hypothesis[63]. Plaque deposits constitute several years of total production of Aβ, and the 
steady-state equilibrium between production and clearance of A is maintained at kinetic rates of 
~8% per hour[64]. Vascular transport of Aβ across the blood-brain barrier can control Aβ brain 
levels and is impaired upon aging[65][66][67]; this clearance is reduced in AD[68]. This 
equilibrium has been thought to be perturbed to gradually increase steady-state levels of toxic Aβ 
consistent with the buildup of plaques[28]. This version of the hypothesis was a quantitative gain 
of toxic function (or "toxic by degree") mechanism, i.e. quantitative levels were seen as a 
defining culprit of disease, supported by the major plaque deposits.  
 However, many FAD-causing mutations in PSEN1 do not generally increase A 
production but actually often lower it[58][69]. Neuro-degeneration and cognitive decline does 
not correlate with the amount of A plaques[11,12]. Also, 20−40% of cognitively normal people 
have A plaques in amounts typical for the disease[70]. Thus, total A load, which is dominated 
by the extracellular plaque pool, relates little to disease progress. This led to modification of the 
paradigm to imply that not the total A levels, but the ratio between long and short forms of Aβ 
(mostly Aβ42/Aβ40) are molecular determinants of disease[29][71]; Aβ42 is well-established to be 
more toxic than Aβ40[6][9], so this argument had support.  
 Soluble oligomers of Aβ, as first reported by Yankner et al.[72], are more cytotoxic than 
the fibrils making up the major Aβ plaques[73][74]. The toxicity of oligomers is very dependent 
on size and conformation[75], and both A-dimers and trimers[76] have been identified as 
particularly toxic[77]. Yet, the assignment of a single pathogenic form and mechanism of Aβ 
remains elusive[78][79]. However recently, toxicities of genetic A variants were found to 
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correlate significantly with conformational features of the peptide variants, with disordered coil 
structures being more toxic[80]. The toxicity of oligomers depends on structural features as the 
peptide converts from unstructured monomer to the increasingly -sheet structured 
oligomers[81]; these findings suggest that qualitative, rather than quantitative, features of A can 
in principle cause disease (i.e. "toxic by kind"). 
 The toxic mechanism of Aβ42-enriched oligomers supposedly causing AD remains highly 
debated, and several toxic modes of action have been suggested[82]: They may lead to 
impairment of long-term potentiation[83], permeabilization of cell membranes[84][85], 
oxidative stress[86], and calcium dyshomeostasis[87][88]. Exposure of hydrophobic parts of the 
A variants is likely to cause aggregation and, in various contexts, interactions with membranes 
and other molecules in the cell to aggravate the toxicity of the peptides[85][89][90]. Aβ has a 
hydrophilic and a hydrophobic part well-suited for membrane interaction, and multiple studies 
have documented interaction with membranes[84][85][91] and disruption of prion-protein 
interaction with NMDA receptors[92] and of the respiratory chains of mitochondria[93][94][95].  
 Many of the characterized FAD-causing mutations in PSEN1 impair γ-secretase function 
while increasing the A42/A40 ratio[69][96]; some do so while increasing, others while 
decreasing total A levels which are dominated by the A40 isoform[97][98]. Indeed, increased 
proficiency of so many mutations would be a priori unlikely, as proteins are optimized by 
evolution to perform optimally under the constraints given, and thus most mutations tend to be 
hypomorphic[99]. PSEN1 mutations also tend to be dominant, i.e. heterozygote carriers are 
likely to develop AD; this feature is usually interpreted as a gain-of-toxic function because the 
compensatory presence of the wild type does not prevent disease[69]. Thus, the rationale for 
inhibiting γ-secretase in the first place, to create phenotypes resembling the FAD-causing 
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mutants, seems questionable, and indeed, such inhibitors have produced adverse cognitive 
effects[13][100].  
 The amyloid hypothesis has recently been reviewed and arguments in its favor have been 
compiled[101]. The reader may view the present paper as a counter view to the idea that a gain 
of function of Aβ causes AD and that therapeutic strategies should accordingly focus on Aβ 
containment. 
 
Ten challenges of the amyloid hypothesis 
Among challenges of the amyloid hypothesis, the following ten may be considered noteworthy:  
 (i) The “normal plaques” anomaly: 20−40% of normal elderly have been found by 
Aizenstein et al. to possess high loads of A plaques[70], and many such people have enough 
plaques to satisfy common AD diagnosis criteria[102][103]; this anomaly was frequently 
mentioned[8][104][105]. The amyloid-centric solution to this anomaly is that these normal 
deposits represent pre-clinical disease states[106]; this hypothesis remains to be tested by 
carefully monitoring cognitively normal people for emerging clinical indications of AD over 
several years, correlated against measured plaque load. However, many of these plaques are 
diffuse and not directly related to pathogenicity[101]; thus the significance of the plaque deposits 
to disease progress needs to be further addressed.   
 This challenge also relates to the quality of biomarkers: The Aβ-related biomarkers 
currently used are Aβ42 levels in the cerebrospinal fluid and Positron Emission Tomography 
(PET) imaging of Aβ plaque deposits[111], which usually accompanies AD diagnosis[18][402]; 
this method identifies Aβ deposition early in AD pathology, in support of a role of Aβ imbalance 
in AD[101]. However, plaque deposits are no longer considered pathogenic 
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themselves[106][107][108][109]. Furthermore, the tendency to form plaque-like aggregates does 
not correlate with clinical severity of a Aβ variants[9], and plaques are less toxic than various 
intracellular forms of Aβ[112][113][114][115]. PET does not primarily measure the supposedly 
pathogenic forms of Aβ[72], since these forms differ substantially in size and 
structure[75][76][77]. In addition, it is unlikely that the current therapies target the oligomer 
types Aβ that cause disease[78][79]. Thus, while PET imaging clearly provides important insight 
into disease features, we need to know much more about the specific molecular forms of Aβ 
relevant to different stages of the disease[117][118].  
 (ii) The Aβ-localization-neurodegeneration anomaly: A is expressed throughout the 
brain, but AD initiates in specific parts of the brain, i.e. additional factors contribute to disease, 
as first observed by Gomez-Isla et al.[107] and later confirmed by Schmitz al.[108]. This point 
was cited as an anomaly by Bush and Tanzi[109] and has been repeated in later lists of 
anomalies[8][104][105]. The missing factors explaining why some areas are first hit by AD need 
to be accounted for.  
(iii) The neglect of normal function: The normal functions of the central players, A and 
APP, are not incorporated into the current form of the amyloid hypothesis, although A serves 
beneficial roles in the normal brain[110][111]. The presence of normal functions of Aβ 
complicates the idea that Aβ is simply a toxic peptide whose overload triggers AD[112]. A has 
a therapeutic window, with concentrations below nano-molar (as encountered within cells) being 
neurotrophic and higher concentrations (as seen in research models of the disease) being 
toxic[113][114], yet the amyloid hypothesis[101] focuses only on one side of this equation. 
Normal functions of Aβ are documented in multiple studies: Loss of A40 upon secretase 
inhibition or A antibodies kills cultured neurons[115] and impairs neuronal activity in 
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mice[110]. Aβ may also protect against metal-induced toxicity[111] and regulate vesicle release 
in hippocampal synapses[116]. Also, the innate immune system[117][118] and pathogen 
responses[119] are related to Aβ imbalances, and Aβ can act as a pro-inflammatory agent in such 
cases[120]. The recently identified roles of infections in elevating AD risk show that 
inflammatory trauma plays a major role in AD pathology[121][122][123][124]. Clearly, the 
functions of and responses to Aβ within the neurons are still very far from understood and 
substantially more complicated than the current overload mechanism implies. 
 (iv) The divide between familial and sporadic AD: The amyloid hypothesis is essentially 
a FAD hypothesis: It is based on inherited mutations in APP and PSEN and its research models 
involve such genetic mutations known to overexpress A. This approach is very narrow and 
certainly does not accurately depict the ~95% sporadic cases caused by risk factors not relating 
to A, which should be explained. There is thus an urgent need to understand in combination the 
biochemical causes of the two forms of disease, e.g. by developing sporadic models of AD based 
on chemical-aging instead of mutations.   
 v) Data heterogeneity reduces interpretative value of disease models based on APP 
variants: A main basis for the amyloid hypothesis is the overexpression of FAD-related APP 
mutations in cells and mice. These mutations are located both within (e.g. the Dutch and Italian 
mutation) and outside (e.g. the Swedish mutation) the Aβ region[9]. The protective A2T 
mutation[125] has been widely used as a showcase of the amyloid hypothesis[101], and its lower 
produced A levels fit well to quantitative gain of function as the protective alternative to the 
Swedish mutation and A2V[126]. The Swedish mutation produces very high A levels and is the 
most used transgenic mouse model in AD research[127], yet it only models the type of 
overproduction of A consistent with the now obsolete "cascade" hypothesis.  
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 However, the phenotypes of APP variants are very heterogeneous, a fact sometimes 
overlooked when focusing on a specific variant[9]. Some of these mutations increase the 
A42/A40 ratio, others lower it. Some are more toxic than wild-type forms, others not 
significantly so. Some aggregate quickly, others relatively slowly. The EC50 values of A 
variants vary substantially and do not correlate with clinical disease characteristics, and reported 
aggregation propensities are challenged by measurement uncertainties and differences in lab 
protocols[9]. This implies that the widely used research models have little, if anything, to do 
with the gradually disturbed amyloid imbalances of the aging human brain[9]. Even in terms of 
clinical manifestation, APP variations can give rise to either cerebral amyloid angiopathy (CAA) 
or classical AD, reflected in differences in the intensity of tangles and plaques[9]. This 
biochemical and clinical heterogeneity is not accounted for by the amyloid hypothesis, which 
tends to focus on transgenic models where amyloid levels are uniformly increased, a model that 
presumes quantitative, rather than qualitative, gain of function. 
 The trisomy 21 AD-related phenotype is often cited in support of the amyloid hypothesis 
as a clear-cut case of quantitative gain of function[101]. However, if one looks at the APP 
phenotypes in total, quantitative gain cannot by itself explain AD as many mutations in both 
APP and PSEN1 do not increase Aβ levels[9]. Also, A2V, H6R, and D7N variants (using Aβ 
numbering) lead to Aβ42/Aβ40 ratios similar to wild type, but E22G, E22K, and E22Q actually 
lower the Aβ42/Aβ40 ratio[9]. Still, drug development programs are directed towards reducing the 
amount of A based on a quantitative gain of function mechanism that clearly does not represent 
the multitude of manifestations of the FAD mutant phenotypes. The phenotypes of APP variants 
in their totality strongly suggest that overexpression is a side effect of some APP mutations, but 
not itself the cause of disease[9]. 
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 vi) Toxicity does not reflect pathogenicity: The amyloid hypothesis lends support from 
specific A toxicities measured in cultured cells. Many reported Aβ cytotoxicities[128] and 
aggregation tendencies[129] occurred at micro-molar concentrations, representative of ~1 year of 
total brain production, administered locally and instantaneously at 1000-fold higher than 
biological concentrations[130][131]; yet the true human disease is age-dependent and only 
manifest very gradually. Arguably, many amyloid toxicity studies simply prove the principle of 
Paracelsus that the dose makes the poison and are hardly informative. Some toxic modes 
associated with physiologically relevant concentrations have been reported[76], and more 
research in this direction seems required. Yet, quantitative measures of clinical severity (age of 
onset, survival times) of genetic Aβ variants do not correlate with measured toxicities[9]. Thus, 
any relation between toxicity in cells and mice and the real human aging brain disease remains 
speculative and potentially explains why such research models have not produced successful 
clinical treatments.  
 (vii) The absence of genetic risk factors relating to A turnover: Many more mutations in 
PSEN1 than in APP cause AD, although APP contains the final A product; this anomaly was 
first emphasized by Shen and Kelleher[132]. Also, the shortage of β- and α-secretase mutations 
and mutations in zinc peptidases such as insulin degrading enzyme involved in amyloid 
degradation undermine the concept that APP cleavage and Aβ production is central to disease. 
The FAD-related mutations, and in particular the absent FAD-related mutations, argue for a 
secondary role of APP processing (and hence, amyloid buildup) relative to other functions.  
 (viii) The curious nature of the Aβ42/Aβ40 ratio: Many FAD mutations tend to lower the 
levels of both amyloid isoforms, and the amyloid hypothesis relies on the Aβ42/Aβ40 ratio to 
argue why PSEN mutations cause AD[13][133], yet the curious nature of only this ratio (but not 
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total levels of Aβ42) being pathogenic remains to be explained, i.e. how does this produce gradual 
buildup of toxic oligomers emphasized by the amyloid hypothesis[133]. This ratio has recently 
been directly correlated to clinical severity, although this does not necessarily imply 
causation[97]. It could be that reduced enzymatic function causes disease and that higher ratios is 
a side consequence[132][134].  
 Some possible solutions to this anomaly can be suggested: A competitive seeding that 
depends on relative amounts of isoforms rather than total Aβ42 levels (which tend to also 
decrease in PSEN1 phenotypes) could mean that local surplus of longer isoforms seed 
degradation-resistant oligomers that enable a gradual buildup of oligomers. Also, one could 
imagine that hetero-oligomers enriched in longer isoforms may be less prone to degradation, thus 
causing a gradual buildup of pathogenic oligomer pools. Such mechanisms could demystify the 
Aβ42/Aβ40 ratio as a culprit of disease and provide it with a mechanistic basis. 
 (ix) The aging effect: The amyloid hypothesis does not explain the main risk factor, age, 
i.e. why Aβ gradually accumulates but then transits into gradual cognitive impairment and AD, 
as emphasized by the two-hit hypothesis[135]. The aging human proteome undergoes 
remarkably systematic changes with a general down-regulation of genes involved in synaptic 
function, including calcium homeostasis and vesicular transport, whereas genes involved in 
stress response, inflammation, lipid metabolism are generally up-regulated[15]. These features 
should be incorporated into models of AD to capture the aging effect, yet the amyloid hypothesis 
has little direct coupling to the aging phenotype.  At the same time, the other important 
histopathological features of AD that relate more directly to chemical aging, e.g. metabolic 
deficiencies, metal ion imbalances, and oxidative stress, are not well accounted for by the 
amyloid hypothesis[104], and these manifestations need also to be explained in relation to 
amyloid imbalance. 
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 (x) Clinical performance: The ultimate test of any disease theory, the development of 
medicine from the principles of the ruling paradigm, has not yet been successful[7][12]; the 
absence of any Aβ-centric drug on the market or indeed any successful phase 3 trial has led to 
calls for modification of the amyloid hypothesis[11]. The most promising current drug 
candidates are antibodies such as solanezumab that target various Aβ forms[136]. Solanezumab 
did not improve cognitive function in the two major phase 3 trials[137], but if one analyses the 
combined data there is a positive effect on cognition that should be explored further[138][139]. 
Aducanumab has also shown several promising data and is currently a promising 
candidate[140][141]. However, another antibody, Bapineuzumab, has been found not to improve 
cognition[142] and produce adverse effects[143] even though it does lower Aβ levels[144]. 
Clearly, we need to understand better these different outcomes, specifically how the various 
antibodies bind and modify the conformations and properties of Aβ, as the various 
conformations of Aβ that are targeted affect pathology differently[7][80]. 
 In many of these cases, the clinical human data were substantially less encouraging than 
the mouse and cell data used to research new treatments[13][100], a troubling finding that is 
however consistent with the poor correlations between human and cell and mouse data from 
meta-analysis[9]. This problem emphasizes two major challenges in current AD research; the 
need for accurate models of the conformational epitopes targeted by therapies and the need for 
preclinical disease models that more accurately reflect the aging human brain. 
 
 
Concluding remarks and perspectives 
The ten challenges above emphasize that new approaches are required if the amyloid paradigm is 
to be retained. While the heterogeneity in clinical data is due to risk modifiers and thus a 
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problem to any paradigm of AD, heterogeneity in Aβ-specific data is due to different lab 
protocols and to the special chemical features of this enigmatic peptide: Efforts are ongoing to 
produce consistent, stable, and reproducible monomeric and oligomeric Aβ samples to remove 
some of the protocol-based heterogeneity[145][146]. Even beyond sample management, the 
structural variability of these highly disordered peptides[147] renders observed properties such 
as toxicity very conformation-dependent, and, since conformation relates to chemical 
environment, observed properties are highly sensitive to concentration, pH, ionic strength, co-
solvents, and the time scale of the experiment[90][148].   
  Considering the major structural variability of Aβ, the "physiologically relevant" Aβ 
structures can be sought by correlating specific structures directly to clinical and biochemical 
data: This provides statistically significant relationships between fundamental chemical 
properties of Aβ variations and their clinical and biochemical phenotypes[80][90][149]: 
Remarkably, hydrophobic exposure in disordered structures correlates with the diagnosis age of 
patients carrying a specific variant, whereas other structures do not. This suggests that these 
disordered conformations of Aβ are the physiologically relevant ones[149]. Also, the differences 
in experimental Aβ toxicities can be explained by distinct structural features, notably the amount 
of hydrophobic exposure seen in the average structural ensemble of each peptide variant, 
providing statistically significant correlations to EC50 data[80][90]. Thus, Aβ aggregation and 
cell toxicity is caused by hydrophobic exposure in specific disordered amyloid states that could 
be targeted by molecular intervention, e.g. antibodies[150][151]. However, in the light of the 
poor correlation between toxicity assays and clinical disease features[9], the question still 
remains whether this oligomerization-driven cell toxicity has anything to do with AD.  
 To move forward on these various challenges, we must i) solve the data heterogeneity 
issue of peptide preparations and measurements; ii) actively use available human patient data 
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that tell us about the real aging human disease, considering the challenges of mouse 
models[127]; iii) unite sporadic and familial disease forms as we move beyond the FAD-
mutation-based research models and towards chemical-aging models that account for the aging 
phenotype as emphasized e.g. by the two-hit hyopothesis[135]; iv) think effectively at the 
proteome rather than single-gene level; v) account for the normal functions of APP and Aβ, as 
their absence within the current paradigm is conspicuous; the elaborate splicing of APP clearly 
occurs in the neurons for a reason; and vi) consider all manifestations of disease, including 
oxidative stress and metal ion imbalances, mitochondrial disease, immune system responses, and 
metabolic deficiencies.  
 The amyloid paradigm may have been an excellent starting point, but it is, as argued 
above, very far from the full solution.    
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